Corrigendum to "Identification of Differential Tumor Subtypes of T1 Bladder Cancer" [Eur. Urol. 78 (2020) 533-537]

Affiliations

• ¹ Dxige Research Inc., Courtenay, BC, Canada.
• ² Cartes d'Identité des Tumeurs Program, Ligue Nationale Contre le Cancer, Paris, France; Oncologie Moleculaire, Institut Curie, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
• ³ Department of Urology, University of Washington, Seattle, WA, USA.
• ⁴ Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
• ⁵ Departments of Urology, Biochemistry, and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• ⁶ Tempus Labs, Inc., Chicago, IL, USA.
• ⁷ Center for Translational Data Science, University of Chicago, Chicago, IL, USA.
• ⁸ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
• ⁹ Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
• ¹⁰ Experimental Developmental Therapeutics Program, UT Health MD Anderson, San Antonio, TX, USA; Department of Urology, UT Health San Antonio, San Antonio, TX, USA.
• ¹¹ Cartes d'Identité des Tumeurs Program, Ligue Nationale Contre le Cancer, Paris, France.
• ¹² Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Curitiba, Brazil.
• ¹³ Departments of Urology, Biochemistry, and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: joshua.meeks@northwestern.edu.